Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Status:
Recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the correct dose and safety of adding a new cancer
drug, venetoclax, to a standard combination of chemotherapy drugs as a second treatment for
relapsed/refractory DLBCL. In this study, venetoclax will be added to RICE (rituximab,
ifosfamide, carboplatin, etoposide), a common set to cancer drugs used as a second line
treatment for relapsed/refractory DLBCL.
Venetoclax, is a new targeted anti-cancer drug, which works by mimicking a particular protein
produced by the tumor and interrupting its normal processes, ultimately causing the tumor
cells to die. Adding venetoclax to the standard RICE regimen is believed to increase the
chance of getting cancer into remission.
Venetoclax is experimental because it is not approved by the Food and Drug Administration
(FDA) for the treatment of relapsed/refractory DLBCL. Venetoclax has been FDA approved for
use in patients with chronic lymphocytic leukemia (CLL).